Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors

Mutations in the isocitrate dehydrogenase-1 and -2 (IDH1/2) genes were first identified in glioma and acute myeloid leukemia (AML), and subsequently found in multiple other tumor types. These neomorphic mutations convert the normal product of enzyme, α-ketoglutarate (αKG), to the oncometabolite 2-hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sule, Amrita, Van Doorn, Jinny, Sundaram, Ranjini K, Ganesa, Sachita, Vasquez, Juan C, Bindra, Ranjit S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Nucleic Acid-Based Cancer Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127964/
https://www.ncbi.nlm.nih.gov/pubmed/34027408
http://dx.doi.org/10.1093/narcan/zcab018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127964/
https://www.ncbi.nlm.nih.gov/pubmed/34027408
http://dx.doi.org/10.1093/narcan/zcab018

Ejemplares similares